PharmacoEconomics & Outcomes News

, Volume 781, Issue 1, pp 32–32 | Cite as

Sacubitril/valsartan cost effective for HF in Netherlands

Clinical study


  1. Corro Ramos I, et al. Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health : 20 Jun 2017. Available from: URL:

Copyright information

© Springer International Publishing AG  2017

Personalised recommendations